GENERICally Speaking Hatch Waxman Bulletin

The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.

GENERICally Speaking: A Hatch-Waxman Litigation Bulletin

The Summer 2022 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.

In this issue we review Q2 cases and issue(s) presented:

Relevant ANDA updates highlighted in this issue:

Oren D. Langer

Partner

Managing Partner, New York Office

New Drug Applications and 505(b)(2) Applications
Abbreviated New Drug Applications and 505(b)(2) Applications
Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act

GENERICally Speaking: A Hatch-Waxman Litigation Bulletin - Q1

GENERICally Speaking: A Hatch-Waxman Litigation Bulletin - Q4